Meeting Banner
Abstract #1462

Preliminary Experience in Off-Label Use of Ferumoxytol Contrast-enhanced Magnetic Resonance Angiography in Pregnancy

Lindsay M Griffin1, Kim-Lien Nguyen2, Thomas M Grist1, Christopher J Francois1, Scott B Reeder3, J Paul Finn2, and Mark L Schiebler1

1Radiology, University of Wisconsin, Madison, WI, United States, 2Radiology and Medicine, University of California Los Angeles, Los Angeles, CA, United States, 3Radiology, Medical Physics, Biomedical Engineering, Medicine, and Emergency Medicine, University of Wisconsin, Madison, WI, United States

Recent debate about potential long-term safety of gadolinium-based contrast agents has amplified concerns about their use in pregnancy, greatly limiting options for advanced imaging in this critical patient group. We report our experience on the use of ferumoxytol contrast-enhanced magnetic resonance angiography (MRA) during pregnancy. We identified eight pregnant subjects, at two institutions, with contrast-enhanced MRI/MRA using ferumoxytol. There was one mild possible adverse event during contrast administration. There were no premature deliveries (< 35 weeks) or birth defects in five babies with available postpartum data. While preliminary, ferumoxytol holds promise as a versatile MR contrast agent in pregnancy.

This abstract and the presentation materials are available to members only; a login is required.

Join Here